Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

534.05 -0.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

511.01

Максимум

534.8

Ключови измерители
By Trading Economics
Приходи	36M -58M
Продажби	53M 364M
EPS	-1.99
Марж на печалбата	-15.906
Служители	915
EBITDA	30M -56M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+33.34% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-803M 12B
Предишно отваряне	534.18
Предишно затваряне	534.05

Настроения в новините

By Acuity

50%

135 / 340 Класиране в Healthcare

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.08.2026 г., 19:16 ч. UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7.08.2026 г., 20:02 ч. UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6.08.2026 г., 21:01 ч. UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4.08.2026 г., 20:04 ч. UTC

Social Media

News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3.08.2026 г., 19:31 ч. UTC

News

Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31.07.2026 г., 23:06 ч. UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30.07.2026 г., 19:27 ч. UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29.07.2026 г., 22:26 ч. UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28.07.2026 г., 18:46 ч. UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27.07.2026 г., 23:56 ч. UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20.07.2026 г., 16:02 ч. UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

33.34% нагоре

12-месечна прогноза

Среден 687.15 USD 33.34%

Висок 962 USD

Нисък 543 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.